Mabion S.A. (MAB.WA)

PLN 9.49

(-4.33%)

Market Cap (In PLN)

153.38 Million

Revenue (In PLN)

151.67 Million

Net Income (In PLN)

41.26 Million

Avg. Volume

46.06 Thousand

Currency
PLN
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
9.48-21.18
PE
-
EPS
-
Beta Value
0.995
ISIN
PLMBION00016
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Krzysztof Kaczmarczyk
Employee Count
-
Website
https://www.mabion.eu
Ipo Date
2010-08-10
Details
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.